

Caterina Stelitano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3123242/publications.pdf>

Version: 2024-02-01

96
papers

6,540
citations

81743

39
h-index

64668

79
g-index

96
all docs

96
docs citations

96
times ranked

5770
citing authors

#	ARTICLE	IF	CITATIONS
1	Early Interim 2- ¹⁸ F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 3746-3752.	0.8	799
2	High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. <i>Lancet</i> , 2009, 374, 1512-1520.	6.3	588
3	Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. <i>Blood</i> , 2004, 103, 2474-2479.	0.6	549
4	ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 805-811.	0.8	256
5	R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Follicular Lymphoma: Results of the FOLLO5 Trial Conducted by the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2013, 31, 1506-1513.	0.8	223
6	The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. <i>Haematologica</i> , 2006, 91, 475-81.	1.7	213
7	ABVD Versus Modified Stanford V Versus MOPPEBVCAD With Optional and Limited Radiotherapy in Intermediate- and Advanced-Stage Hodgkin's Lymphoma: Final Results of a Multicenter Randomized Trial by the Intergruppo Italiano Linfomi. <i>Journal of Clinical Oncology</i> , 2005, 23, 9198-9207.	0.8	167
8	<i>Chlamydomphila Psittaci</i> Eradication With Doxycycline As First-Line Targeted Therapy for Ocular Adnexae Lymphoma: Final Results of an International Phase II Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2988-2994.	0.8	167
9	¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 1769-1775.	0.8	149
10	Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 1905-1912.	0.8	143
11	Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL). <i>Leukemia and Lymphoma</i> , 2015, 56, 921-926.	0.6	139
12	Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. <i>Blood</i> , 2015, 126, 950-956.	0.6	138
13	Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002); Tj ETQq1 1 0.784314 rgBT /Over 5.1 135		
14	Interim Positron Emission Tomography Response—Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 1376-1385.	0.8	128
15	Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim PET positive after two ABVD courses. <i>British Journal of Haematology</i> , 2011, 152, 551-560.	1.2	127
16	Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. <i>British Journal of Haematology</i> , 2012, 156, 346-353.	1.2	122
17	Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. <i>European Journal of Cancer</i> , 2004, 40, 1682-1688.	1.3	118
18	Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. <i>Oncogene</i> , 2005, 24, 2461-2473.	2.6	118

#	ARTICLE	IF	CITATIONS
19	Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. <i>Blood</i> , 2009, 114, 4696-4702.	0.6	114
20	Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 689-696.	0.8	107
21	Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2017, 18, 1076-1088.	5.1	100
22	Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2016, 34, 1175-1181.	0.8	94
23	Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. <i>Haematologica</i> , 2008, 93, 398-404.	1.7	92
24	Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2007, 48, 56-64.	0.6	86
25	CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates β -galactosylceramide presentation to natural killer T lymphocytes. <i>International Journal of Cancer</i> , 2004, 109, 402-411.	2.3	78
26	Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi. <i>Leukemia and Lymphoma</i> , 2012, 53, 581-588.	0.6	74
27	Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2014, 55, 38-43.	0.6	72
28	Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R ² E regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy. <i>Hematological Oncology</i> , 2013, 31, 143-150.	0.8	66
29	The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. <i>Lancet Haematology</i> , the, 2016, 3, e467-e479.	2.2	63
30	Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2013, 160, 207-215.	1.2	57
31	Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. <i>Leukemia Research</i> , 2005, 29, 961-966.	0.4	56
32	Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2014, 99, 489-496.	1.7	55
33	Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses. <i>Genes Chromosomes and Cancer</i> , 2005, 42, 117-127.	1.5	49
34	The prognostic value of positron emission tomography performed after two courses (<sc>INTERIM-PET</sc>) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL). <i>American Journal of Hematology</i> , 2015, 90, 499-503.	2.0	49
35	Peripheral blood CD38 expression predicts survival in B-cell chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2001, 25, 927-932.	0.4	48
36	Long-Term Follow-Up Analysis of HD9601 Trial Comparing ABVD Versus Stanford V Versus MOPP/EBV/CAD in Patients With Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma: A Study From the Intergruppo Italiano Linfomi. <i>Journal of Clinical Oncology</i> , 2011, 29, 4227-4233.	0.8	47

#	ARTICLE	IF	CITATIONS
37	Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléculas Onco-Hematológicas retrospective study. <i>Leukemia and Lymphoma</i> , 2013, 54, 53-57.	0.6	42
38	Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study. <i>British Journal of Haematology</i> , 2018, 183, 755-765.	1.2	41
39	Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas. <i>Cancer</i> , 2004, 101, 1601-1608.	2.0	40
40	Prognostic relevance of serum λ 2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. <i>Haematologica</i> , 2007, 92, 1482-1488.	1.7	38
41	MATILDE chemotherapy regimen for primary CNS lymphoma. <i>Neurology</i> , 2014, 82, 1370-1373.	1.5	38
42	Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 729-739.	0.8	34
43	Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma. <i>Haematologica</i> , 2002, 87, 1192-9.	1.7	34
44	Incidence of second neoplasia in patients with B-cell chronic lymphocytic leukemia treated with chlorambucil maintenance chemotherapy. <i>Leukemia and Lymphoma</i> , 2006, 47, 2314-2320.	0.6	32
45	MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients. <i>Haematologica</i> , 2019, 104, e25-e28.	1.7	32
46	Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 42-49.	0.4	31
47	Clinical Relevance of the Dose of Cytarabine in the Upfront Treatment of Primary CNS Lymphomas with Methotrexate-Cytarabine Combination. <i>Oncologist</i> , 2011, 16, 336-341.	1.9	30
48	Reduced intensity <i>VEPEMB</i> regimen compared with standard <i>ABVD</i> in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (<i>FIL</i>). <i>British Journal of Haematology</i> , 2016, 172, 879-888.	1.2	29
49	Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (<i>FIL</i>) multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e34-e44.	2.2	29
50	Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma. <i>Cancer</i> , 2003, 98, 2393-2401.	2.0	28
51	Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e137-e146.	2.2	28
52	Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study. <i>Leukemia and Lymphoma</i> , 2015, 56, 3281-3287.	0.6	25
53	Treatment of Indolent B-Cell Nonfollicular Lymphomas: Final Results of the LL01 Randomized Trial of the Gruppo Italiano per lo Studio dei Linfomi. <i>Journal of Clinical Oncology</i> , 2003, 21, 1459-1465.	0.8	23
54	ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project. <i>Blood Advances</i> , 2021, 5, 640-648.	2.5	22

#	ARTICLE	IF	CITATIONS
55	Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas. <i>Cancer</i> , 2012, 118, 3954-3961.	2.0	21
56	Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2017, 102, e203-e206.	1.7	21
57	IgV gene intraclonal diversification and clonal evolution in B-cell chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2004, 133, 060118040555003.	1.2	20
58	Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL). <i>Supportive Care in Cancer</i> , 2011, 19, 1505-1510.	1.0	20
59	Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18F-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study. <i>British Journal of Haematology</i> , 2017, 178, 588-591.	1.2	20
60	Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients. <i>European Journal of Haematology</i> , 2007, 78, 35-40.	1.1	16
61	Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Cancers</i> , 2021, 13, 3240.	1.7	16
62	Surface CD14 positivity in B-cell chronic lymphocytic leukaemia is related to clinical outcome. <i>British Journal of Haematology</i> , 1999, 107, 347-352.	1.2	14
63	Assessment of the frequency of additional cancers in patients with splenic marginal zone lymphoma. <i>European Journal of Haematology</i> , 2006, 76, 134-140.	1.1	14
64	Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-III trial. <i>Haematologica</i> , 2019, 104, 2241-2248.	1.7	13
65	In vitro drug-induced cytotoxicity predicts clinical response to fludarabine in B-cell chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 1998, 102, 528-531.	1.2	12
66	Bisphosphonates associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time. <i>American Journal of Hematology</i> , 2009, 84, 850-852.	2.0	12
67	The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL. <i>Blood Advances</i> , 2020, 4, 2011-2017.	2.5	12
68	Chemoresistance As a Function of the Pretherapy Tumor Burden and the Chemotherapy Regimen Administered: Differences Observed With 2 Current Chemotherapy Regimens for Advanced Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 396-402.	0.2	11
69	Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL). <i>Annals of Hematology</i> , 2011, 90, 323-330.	0.8	10
70	Response-Guided ABVD Chemotherapy plus Involved-Field Radiation Therapy for Intermediate-Stage Hodgkin Lymphoma in the Pre-Positron Emission Tomography Era: A Gruppo Italiano Studio Linfomi (GISL) Prospective Trial. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 138-144.	1.4	9
71	A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 880-887.	0.6	9
72	Diagnostic and Prognostic Relevance of the Immunophenotype in Acute Myelocytic Leukemia. <i>Tumori</i> , 1991, 77, 28-31.	0.6	8

#	ARTICLE	IF	CITATIONS
73	Prospective Study of Indolent Non-follicular Non-Hodgkin's Lymphoma: Validation of Gruppo Italiano Per Lo Studio Dei Linfomi (GISL) Prognostic Criteria for Watch and Wait Policy. <i>Leukemia and Lymphoma</i> , 2002, 43, 1933-1938.	0.6	8
74	The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study. <i>European Journal of Haematology</i> , 2006, 76, 217-229.	1.1	8
75	Tumor burden in Hodgkin's lymphoma can be reliably estimated from a few staging parameters. <i>Oncology Reports</i> , 2012, 28, 815-820.	1.2	8
76	Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (>70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL). <i>Leukemia and Lymphoma</i> , 2019, 60, 2890-2898.	0.6	8
77	Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	8
78	High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients. <i>American Journal of Hematology</i> , 2006, 81, 973-978.	2.0	7
79	B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL). <i>Leukemia and Lymphoma</i> , 2016, 57, 2375-2381.	0.6	7
80	Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation. <i>Hematological Oncology</i> , 2020, 38, 257-265.	0.8	7
81	Bleomycin, Epidoxorubicin, Cyclophosphamide, Vincristine and Prednisone (BACOP) in Patients with Follicular Non-Hodgkin's Lymphoma: Results of a Prospective, Multicenter Study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL). <i>Leukemia and Lymphoma</i> , 2002, 43, 1795-1801.	0.6	6
82	Administration of recombinant human erythropoietin alpha before autologous stem cell transplantation reduces transfusion requirement in multiple myeloma patients. <i>Supportive Care in Cancer</i> , 2005, 13, 182-187.	1.0	6
83	Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma. <i>Cancer</i> , 2009, 115, 1906-1913.	2.0	6
84	The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study. <i>Haematologica</i> , 2015, 100, 517-524.	1.7	6
85	Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. <i>Oncology Reports</i> , 2009, 21, 1029-35.	1.2	5
86	Anemia prevalence and treatment practice in patients with non-myeloid tumors receiving chemotherapy. <i>Cancer Management and Research</i> , 2013, 5, 205.	0.9	5
87	Clinical characteristics of interim-PET negative patients with a positive end PET from the prospective HD08-01 FIL study. <i>Annals of Hematology</i> , 2020, 99, 283-291.	0.8	5
88	The Early- and Intermediate-Term Toxicity to Primitive Hematopoietic Progenitor Cells of Three Chemotherapy Regimens for Advanced Hodgkin Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 425-429.	1.4	4
89	A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up. <i>Acta Haematologica</i> , 2017, 137, 7-14.	0.7	4
90	A brief rituximab, bendamustine, mitoxantrone (RBM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL). <i>British Journal of Haematology</i> , 2021, 193, 280-289.	1.2	4

#	ARTICLE	IF	CITATIONS
91	Role of glutathione-s-transferase (gst) polymorphisms in patients with advanced hodgkin lymphoma: results from the hd2000 GISL trial. <i>Leukemia and Lymphoma</i> , 2012, 53, 406-410.	0.6	3
92	Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi. <i>Leukemia and Lymphoma</i> , 2010, 51, 422-429.	0.6	2
93	Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma. <i>British Journal of Haematology</i> , 2021, 192, 1011-1014.	1.2	2
94	A Patient with Chronic Lymphocytic Leukemia and Bone Localization: A Case Report. <i>Blood</i> , 2015, 126, 5301-5301.	0.6	1
95	A rare case of appendicular skeleton localization in a patient with chronic lymphocytic leukemia successfully treated with salvage radiation therapy. <i>Advances in Radiation Oncology</i> , 2018, 3, 121-124.	0.6	0
96	Relapsing/refractory HL after autotransplantation: which treatment?. <i>Acta Biomedica</i> , 2020, 91, 30-40.	0.2	0